Previous studies to date concerning IL-36 in tumorigenesis have predominantly focused on the effectiveness of IL-36R agonists in stimulating cells within the TME to favour tumour rejection by immune populations such as CD4+, CD8+ T cells and NK cell through activation and/or proliferation [35]. The gene discussed is IL1RL2; the disease is neoplasm.